A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This was a multicenter, randomized, double-blind, placebo-controlled study of patients with
severe, though stable, cystic fibrosis (CF) whose routine treatment included Pulmozyme.
Patients were randomized to either continue Pulmozyme or have therapy withdrawn for 2 weeks
(placebo group). Patients must have had stable CF symptoms without any change in therapy for
2 weeks prior to enrollment in order to participate.